Which has better earnings and valuation, INSM or TGTX?

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 45.29 -$1.28B -$4.11 N/A TG Therapeutics $616.29M 13.48 $447.18M $2.74 19.81

Is INSM or TGTX more profitable?

TG Therapeutics has a net margin of 55.22% compared to Insmed's net margin of -76.94%. TG Therapeutics' return on equity of 73.49% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% TG Therapeutics 55.22% 73.49% 34.14%

Which has preferable valuation and earnings, ROIV or TGTX?

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,174.36 -$299.77M -$0.53 N/A TG Therapeutics $616.29M 13.48 $447.18M $2.74 19.81

Does the media prefer ROIV or TGTX?

In the previous week, Roivant Sciences had 9 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for Roivant Sciences and 10 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.88 beat Roivant Sciences' score of 0.48 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TGTX or MRNA more profitable?

TG Therapeutics has a net margin of 55.22% compared to Moderna's net margin of -141.43%. TG Therapeutics' return on equity of 73.49% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 55.22% 73.49% 34.14% Moderna -141.43% -28.30% -19.39%

Does the media favor TGTX or MRNA?

In the previous week, Moderna had 103 more articles in the media than TG Therapeutics. MarketBeat recorded 113 mentions for Moderna and 10 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.88 beat Moderna's score of 0.40 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 46 Very Positive mention(s) 16 Positive mention(s) 14 Neutral mention(s) 18 Negative mention(s) 14 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, INCY or TGTX?

Incyte has higher revenue and earnings than TG Therapeutics. Incyte is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 5.04 $1.29B $7.85 16.28 TG Therapeutics $616.29M 13.48 $447.18M $2.74 19.81

Is INCY or TGTX more profitable?

TG Therapeutics has a net margin of 55.22% compared to Incyte's net margin of 27.71%. TG Therapeutics' return on equity of 73.49% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% TG Therapeutics 55.22% 73.49% 34.14%

Does the media refer more to INCY or TGTX?

In the previous week, Incyte had 17 more articles in the media than TG Therapeutics. MarketBeat recorded 27 mentions for Incyte and 10 mentions for TG Therapeutics. Incyte's average media sentiment score of 1.04 beat TG Therapeutics' score of 0.88 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 18 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TGTX or BNTX?

In the previous week, BioNTech had 9 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for BioNTech and 10 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.88 beat BioNTech's score of 0.16 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Neutral

TG Therapeutics (TGTX) Competitors

$54.27 +3.71 (+7.34%)

As of 08/21/2026 04:00 PM Eastern

Compare

TGTX vs. INSM, ROIV, MRNA, INCY, and BNTX

Should you buy TG Therapeutics stock or one of its competitors? TG Therapeutics's main competitors and comparable companies include Insmed (INSM), Roivant Sciences (ROIV), Moderna (MRNA), Incyte (INCY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TG Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

58.6% of TG Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

TG Therapeutics has a net margin of 55.22% compared to Insmed's net margin of -76.94%. TG Therapeutics' return on equity of 73.49% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
TG Therapeutics	55.22%	73.49%	34.14%

Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

Insmed presently has a consensus price target of $205.52, indicating a potential upside of 63.41%. TG Therapeutics has a consensus price target of $63.00, indicating a potential upside of 16.09%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Insmed is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, TG Therapeutics had 10 more articles in the media than Insmed. MarketBeat recorded 10 mentions for TG Therapeutics and 0 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat TG Therapeutics' score of 0.88 indicating that Insmed is being referred to more favorably in the media.

Company	Overall Sentiment
Insmed	Positive
TG Therapeutics	Positive

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A
TG Therapeutics	$616.29M	13.48	$447.18M	$2.74	19.81

Summary

TG Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Roivant Sciences had 9 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for Roivant Sciences and 10 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.88 beat Roivant Sciences' score of 0.48 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,174.36	-$299.77M	-$0.53	N/A
TG Therapeutics	$616.29M	13.48	$447.18M	$2.74	19.81

TG Therapeutics has a net margin of 55.22% compared to Roivant Sciences' net margin of -3,534.96%. TG Therapeutics' return on equity of 73.49% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
TG Therapeutics	55.22%	73.49%	34.14%

Roivant Sciences currently has a consensus target price of $35.14, suggesting a potential downside of 3.21%. TG Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 16.09%. Given TG Therapeutics' higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

TG Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Moderna?

TG Therapeutics (NASDAQ:TGTX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TG Therapeutics has a net margin of 55.22% compared to Moderna's net margin of -141.43%. TG Therapeutics' return on equity of 73.49% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Moderna	-141.43%	-28.30%	-19.39%

TG Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

TG Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.48	$447.18M	$2.74	19.81
Moderna	$1.94B	29.79	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 103 more articles in the media than TG Therapeutics. MarketBeat recorded 113 mentions for Moderna and 10 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.88 beat Moderna's score of 0.40 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	46 Very Positive mention(s)	16 Positive mention(s)	14 Neutral mention(s)	18 Negative mention(s)	14 Very Negative mention(s)	Neutral

TG Therapeutics currently has a consensus price target of $63.00, suggesting a potential upside of 16.09%. Moderna has a consensus price target of $69.50, suggesting a potential downside of 52.09%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

TG Therapeutics beats Moderna on 11 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Incyte has higher revenue and earnings than TG Therapeutics. Incyte is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	5.04	$1.29B	$7.85	16.28
TG Therapeutics	$616.29M	13.48	$447.18M	$2.74	19.81

TG Therapeutics has a net margin of 55.22% compared to Incyte's net margin of 27.71%. TG Therapeutics' return on equity of 73.49% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
TG Therapeutics	55.22%	73.49%	34.14%

97.0% of Incyte shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Incyte currently has a consensus price target of $123.10, indicating a potential downside of 3.69%. TG Therapeutics has a consensus price target of $63.00, indicating a potential upside of 16.09%. Given TG Therapeutics' higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.48
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Incyte had 17 more articles in the media than TG Therapeutics. MarketBeat recorded 27 mentions for Incyte and 10 mentions for TG Therapeutics. Incyte's average media sentiment score of 1.04 beat TG Therapeutics' score of 0.88 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	18 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Incyte beats TG Therapeutics on 9 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to BioNTech?

TG Therapeutics (NASDAQ:TGTX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, BioNTech had 9 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for BioNTech and 10 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.88 beat BioNTech's score of 0.16 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Neutral

TG Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

TG Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.48	$447.18M	$2.74	19.81
BioNTech	$3.25B	9.08	-$1.29B	-$7.83	N/A

TG Therapeutics has a net margin of 55.22% compared to BioNTech's net margin of -63.54%. TG Therapeutics' return on equity of 73.49% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
BioNTech	-63.54%	-6.86%	-6.00%

TG Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 16.09%. BioNTech has a consensus target price of $127.81, indicating a potential upside of 9.64%. Given TG Therapeutics' higher possible upside, equities analysts clearly believe TG Therapeutics is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

TG Therapeutics beats BioNTech on 11 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TGTX vs. The Competition

Export

Metric	TG Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.31B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	19.81	11.62	272.60	24.25
Price / Sales	13.48	1,334.62	624.33	101.47
Price / Cash	19.37	105.14	78.62	53.99
Price / Book	13.74	16.80	13.05	6.20
Net Income	$447.18M	-$12.50M	$3.47B	$348.59M
7 Day Performance	11.35%	3.29%	2.09%	0.08%
1 Month Performance	-2.22%	8.23%	6.64%	3.88%
1 Year Performance	84.34%	55.05%	25.02%	16.98%

TG Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TGTX TG Therapeutics	3.8504 of 5 stars	$54.27 +7.3%	$63.00 +16.1%	+84.3%	$8.31B	$616.29M	19.81	290	News Coverage Options Volume High Trading Volume
INSM Insmed	3.4506 of 5 stars	$128.32 +3.7%	$205.52 +60.2%	-4.6%	$27.02B	$606.42M	N/A	1,664	Positive News
ROIV Roivant Sciences	1.5285 of 5 stars	$36.24 +0.1%	$35.14 -3.0%	+204.5%	$26.15B	$8.26M	N/A	860	Analyst Forecast Insider Trade
MRNA Moderna	1.6511 of 5 stars	$64.46 +1.8%	$42.13 -34.6%	+434.9%	$25.28B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Options Volume
INCY Incyte	3.577 of 5 stars	$123.50 +2.8%	$121.65 -1.5%	+50.3%	$24.36B	$5.14B	15.73	2,844	News Coverage Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Competitors

TGTX vs. INSM, ROIV, MRNA, INCY, and BNTX

How does TG Therapeutics compare to Insmed?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Summary

How does TG Therapeutics compare to Moderna?

Summary

How does TG Therapeutics compare to Incyte?

Summary

How does TG Therapeutics compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Competitors

TGTX vs. INSM, ROIV, MRNA, INCY, and BNTX

How does TG Therapeutics compare to Insmed?

Do insiders & institutionals believe in INSM or TGTX?

Is INSM or TGTX more profitable?

Which has more risk & volatility, INSM or TGTX?

Do analysts recommend INSM or TGTX?

Does the media refer more to INSM or TGTX?

Which has better earnings and valuation, INSM or TGTX?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Does the media prefer ROIV or TGTX?

Which has more risk and volatility, ROIV or TGTX?

Which has preferable valuation and earnings, ROIV or TGTX?

Is ROIV or TGTX more profitable?

Do analysts recommend ROIV or TGTX?

Do institutionals and insiders have more ownership in ROIV or TGTX?

Summary

How does TG Therapeutics compare to Moderna?

Do institutionals & insiders have more ownership in TGTX or MRNA?

Is TGTX or MRNA more profitable?

Which has more volatility & risk, TGTX or MRNA?

Which has better earnings and valuation, TGTX or MRNA?

Does the media favor TGTX or MRNA?

Do analysts rate TGTX or MRNA?

Summary

How does TG Therapeutics compare to Incyte?

Which has more volatility and risk, INCY or TGTX?

Which has stronger valuation and earnings, INCY or TGTX?

Is INCY or TGTX more profitable?

Do institutionals and insiders believe in INCY or TGTX?

Do analysts rate INCY or TGTX?

Does the media refer more to INCY or TGTX?

Summary

How does TG Therapeutics compare to BioNTech?

Does the media prefer TGTX or BNTX?

Which has more volatility and risk, TGTX or BNTX?

Which has higher valuation & earnings, TGTX or BNTX?

Is TGTX or BNTX more profitable?

Do analysts recommend TGTX or BNTX?

Do institutionals & insiders hold more shares of TGTX or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools